Biotin immunoassay interference: A UK-based prevalence study.
Ann Clin Biochem
; 58(1): 66-69, 2021 01.
Article
em En
| MEDLINE
| ID: mdl-32936669
ABSTRACT
BACKGROUND:
Biotin interference in biotin-streptavidin-based immunoassays is increasingly reported due to individuals taking biotin-containing supplements and patients prescribed biotin. The reported prevalence of serum biotin above the lowest threshold (≥10⯵g/L) for interference in Roche Diagnostics immunoassay tests is 0.8% in Australia and 7.4% in the USA. There are, however, no such data in UK populations. In a service evaluation, we therefore studied the prevalence of biotin interference in routine serum samples received in our laboratory.METHODS:
Biotin was measured in 524 anonymized surplus serum samples in which at least one immunoassay test had been requested.RESULTS:
The median (95% confidence intervals) for serum biotin was 0.27 µg/L (0.07-0.93 µg/L). Serum biotin was <10 µg/L in all samples, <5 µg/L in 522 (99.6%) and <1 µg/L in 513 (98.1%) samples. In four samples, serum biotin was ≥2.5 µg/L (0.8%).CONCLUSIONS:
These data indicate that the probability of biotin immunoassay interference in our patient population is extremely low, with the exception of assays reporting the lowest interference thresholds (e.g. Ortho Troponin I assay [threshold ≥2.5 µg/L]).Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Biotina
/
Troponina I
/
Estreptavidina
Tipo de estudo:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
En
Revista:
Ann Clin Biochem
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Reino Unido